In ₹ Crore except Per Share Latest Annual | NATCAPSUQ FY26 | NECLIFE FY26 | AAREYDRUGS FY26 | BALPHARMA FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | — | 68.34× | ◆ 26.71× | 47.52× | |
| P/B | — | ◆ 0.40× | 1.80× | 2.04× | 1.80× | |
| EV/EBITDA | — | ◆ -3.59× | 44.46× | 10.13× | 10.13× | |
| Market Cap | — | ₹231 Cr | ₹270 Cr | ₹168 Cr | ₹231 Cr | |
| Growth | ||||||
| Revenue CAGR 3Y | — | -81.73% | ◆ 96.26% | 0.81% | 0.81% | |
| Revenue CAGR 5Y | — | -64.04% | — | ◆ 4.46% | -29.79% | |
| Net Income CAGR 3Y | — | — | ◆ 100.20% | 34.14% | 67.17% | |
| Revenue YoY (latest Q) | 7.76% | -99.99% | -56.34% | ◆ 34.53% | -56.34% +114% | |
| Net Income YoY (latest Q) | -2.93% | 75.65% | -25.36% | ◆ 445.66% | 75.65% -104% | |
| Profitability | ||||||
| EBITDA Margin | -0.83% | — | 1.52% | ◆ 10.24% | 5.88% -114% | |
| Net Income Margin | -13.17% | -3152.45% | 0.84% | ◆ 2.03% | 0.84% -1668% | |
| Return on Common Equity | -7.27% | -50.30% | 2.64% | ◆ 7.64% | 2.64% -375% | |
| Return on Capital Employed | -6.42% | -10.25% | 2.84% | ◆ 16.49% | 2.84% -326% | |
| Return on Assets | -5.81% | -47.12% | 1.33% | ◆ 1.68% | 1.33% -537% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.49× | ◆ 0.00× | 0.33× | 1.94× | 0.33× +48% | |
| Interest Coverage | -1.71× | -1.69× | 0.86× | ◆ 1.24× | 0.86× -299% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹187 Cr | ₹0 Cr | ₹472 Cr | ₹312 Cr | ₹312 Cr -40% | |
| Net Income | −₹24.7 Cr | −₹293 Cr | ₹4 Cr | ₹6.3 Cr | ₹4 Cr -722% | |
| Total Assets | ₹424 Cr | ₹622 Cr | ₹297 Cr | ₹376 Cr | ₹376 Cr +13% | |
| EPS | ₹-23.84 | ₹-13.4 | ₹1.39 | ₹3.95 | ₹1.39 -1815% | |
| Book Value per Share | ₹225.99 | ₹29.97 | ₹52.86 | ₹51.66 | ₹51.66 +337% | |